Skip to main content

Advertisement

Table 4 Association analyses of the -1154G > A VEGF polymorphism in endometriosis patients compared with women without disease

From: Role of vascular endothelial growth factor polymorphisms (-2578C > A, -460 T > C, -1154G > A, +405G > C and +936C > T) in endometriosis: a case–control study with Brazilians

-1154G > A Controls Cases OR (95% IC)b DIE Cases OR (95% IC)c Stages III-IV OR (95% IC)d
(n = 106) (n = 161) (n = 131) (n = 97)
N (%) N (%) N (%) N (%)
Genotypes        
GG 74 (69.8) 90 (55.9) 1a 75 (57.3) 1a 56 (57.7) 1a
GA 30 (28.3) 56 (34.8) 1.54 (0.90 - 2.63) 44 (33.6) 1.45 (0.82 - 2.54) 29 (29.9) 1.28 (0.69 - 2.37)
AA 2 (1.9) 15 (9.3) 6.17 (1.37 - 27.8) 12 (9.1) 5.92 (1.28 - 27.4) 12 (12.4) 7.93 (1.70 - 36.9)
Non-GG (GA + AA) 32 (30.2) 71 (44.1) 1.82 (1.09 - 3.06) 56 (42.7) 1.73 (1.01 - 2.96) 41 (42.3) 1.69 (0.95 - 3.02)
Allele        
G 178 (84.0) 236 (73.3) 1a 194 (74.1) 1a 141 (72.7) 1a
A 34 (16.0) 86 (26.7) 1.90 (1.23 - 2.97) 68 (25.9) 1.83 (1.16 - 2.90) 53 (27.3) 1.97 (1.21 - 3.19)
  1. OR is odds ratio, CI is confidence interval. aReference Group; bControls vs. Cases (All patients with endometriosis); cControls vs. Deeply infiltrating endometriosis patients (DIE); dControls vs. Moderate or severe endometriosis patients (stages III or IV). Due to insufficient DNA samples, some of the patients were not genotyped for -1154G > A SNP.